Format

Send to

Choose Destination
Ann Neurol. 2017 Sep;82(3):479-483. doi: 10.1002/ana.25007. Epub 2017 Aug 22.

Body weight is a robust predictor of clinical progression in Huntington disease.

Author information

1
Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands.
2
Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
3
Department of Neurology, Ulm University Hospital, Ulm, Germany.
4
Department of Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
5
Department of Neurodegenerative Disease, University College London Huntington's Disease Centre, University College London Institute of Neurology, London, United Kingdom.

Abstract

Unintended weight loss is a hallmark of Huntington disease (HD), but it is unknown to what extent weight loss impacts the rate of disease progression. Therefore, using longitudinal data from the Enroll-HD study, we assessed the association between baseline body mass index (BMI) and the rate of clinical progression in 5,821 HD mutation carriers. We found that high baseline BMI was associated with a significantly slower rate of functional, motor, and cognitive deterioration (all p < 0.001), independent of mutant HTT CAG repeat size. Our findings provide strong rationale for exploration of systemic metabolism as a therapeutic target in HD. Ann Neurol 2017;82:479-483.

PMID:
28779551
DOI:
10.1002/ana.25007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center